Premium
Riluzole therapy in cervical dystonia
Author(s) -
Müller Jörg,
Wenning Gregor K.,
Wissel Jörg,
Baldauf Angelika,
Seppi Klaus,
Brenneis Christian,
Poewe Werner
Publication year - 2002
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.1200
Subject(s) - riluzole , cervical dystonia , medicine , refractory (planetary science) , dystonia , botulinum toxin , rating scale , dyskinesia , neurological disorder , anesthesia , physical therapy , central nervous system disease , amyotrophic lateral sclerosis , psychology , parkinson's disease , psychiatry , developmental psychology , physics , disease , astrobiology
We conducted a 6‐week open‐label pilot study with blinded video rating of riluzole (50 mg twice a day) in six patients with cervical dystonia (CD) refractory to botulinum toxin A and oral pharmacological treatment. The Tsui rating scale served as primary efficacy measure and improved significantly under riluzole ( P = 0.002). In three of six patients, the Tsui score improved by more than 30% with a greater 50% reduction in the head tremor/jerk subscore of the Tsui scale. These data suggest that riluzole may be helpful in a subgroup of patients with disabling CD refractory to other therapies. © 2001 Movement Disorder Society.